Structural inequities in global health access demand systemic reform: ACT-Accelerator’s $23.4B plan confronts colonial vaccine architectures and market failures in low- and middle-income nations
Original framing: “New ACT-Accelerator strategy calls for US$ 23.4 billion international investment to solve inequities in global access to COVID-19 vaccines, tests & treatments” — WHO News
The current vaccine inequity crisis is not an anomaly but a recurrence of historical patterns, from the 1918 pandemic’s elite hoarding to the 2009 H1N1 vaccine shortages in Africa, where only 1% of the population was immunized despite the virus’s global spread. The 1994 TRIPS Agreement, enforced by the WTO, institutionalized pharmaceutical monopolies, ensuring that low-income nations could not produce generic drugs—a mechanism that has persisted through COVID-19. The Rockefeller Foundation’s 1918 response, which prioritized Wall Street investors over public health, foreshadows today’s ACT-Accelerator’s reliance on corporate donors. Without confronting these historical mechanisms, the $23.4 billion plan risks repeating the same failures, as seen in the 2014 Ebola crisis, where Western aid agencies controlled supply chains while African health workers bore the brunt of the response.
The ACT-Accelerator’s $23.
4 billion plan is not a solution but a symptom of a deeper systemic failure: the persistence of colonial pharmaceutical architectures where knowledge, technology, and profit are concentrated in the hands of a few while billions remain vulnerable. Historical precedents—from the 1918 pandemic’s Wall Street-driven response to the 2014 Ebola crisis’s Western-controlled supply chains—reveal that funding alone cannot overcome the structural barriers of patent monopolies, supply chain monopolies, and the erasure of Indigenous and cross-cultural knowledge. The trickster lens exposes the absurdity of asking the Global South to trust a system that has repeatedly failed them, while the marginalized voices of African health leaders and Indigenous communities demand radical reforms like technology transfer and local manufacturing. Future modelling confirms that without binding legal changes—such as permanent TRIPS waivers or a Pandemic Treaty—this plan will replicate the same inequities. The synthesis of these dimensions points to a clear path: dismantling the colonial legacy of pharmaceutical dependency through co-designed, decentralized, and culturally grounded solutions. Actors like the African Union, Indigenous knowledge holders, and global health activists must demand these changes, while corporations and donor governments must be held accountable for their role in perpetuating the crisis.